Successful isavuconazole salvage therapy in a patient with invasive mucormycosis.

Abstract

A 45-year-old male with rhinocerebral mucormycosis (Rhizopus oryzae), refractory to liposomal amphotericin B and posaconazole, received isavuconazole salvage therapy. Initial isavuconazole plasma and tissue levels were 0.76-0.86 μg/mL and 1.09-1.38 μg/g. Plasma levels increased to 1.3-3.24 μg/mL with reduced comedication. Isavuconazole was well tolerated, and the patient has remained disease-free 24 months post-antifungal therapy.

• Authors: J Ervens, M Ghannoum, B Graf, S Schwartz
• Journal: Infection (Infection) Vol. 42 Issue 2 Pg. 429-32 (Apr 2014) ISSN: 1439-0973 [Electronic] Germany
• PMID: 24217961 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antifungal Agents
• Nitriles
• Pyridines
• Triazoles
• isavuconazole

Topics

• Antifungal Agents (therapeutic use)
• Brain Diseases (drug therapy, microbiology, surgery)
• Humans
• Male
• Middle Aged
• Mucormycosis (drug therapy, microbiology, surgery)
• Nitriles (therapeutic use)
• Pyridines (therapeutic use)
• Rhizopus (genetics, isolation & purification, physiology)
• Salvage Therapy
• Treatment Outcome
• Triazoles (therapeutic use)